Clinical trials: Social Phobia
Social Anxiety Disorder (SAD)
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
- Trial name
- NCT07193563
- Testing
- ENX-102
- Where
- 20 sites in United States
- Volunteers
- 47 people
- Sponsor
- Engrail Therapeutics INC
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-3 (NCT06358651)
- Testing
- Fasedienol Nasal Spray
- Where
- 24 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Social Anxiety Disorder
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core…
- Trial name
- NCT00332046
- Testing
- GW679769
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess…
- Trial name
- NCT06693609
- Testing
- EMP-01
- Where
- 7 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- atai Therapeutics, Inc.
Social Phobia
Social Anxiety Disorder Study Of Paroxetine
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).
- Trial name
- NCT00318669
- Testing
- Paroxetine hydrochloride hydrate
- Where
- 16 sites in Japan
- Volunteers
- 390 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Bi-Polar Disorder, Autism Spectrum Disorder (ASD)
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder
- Trial name
- NCT07329673
- Testing
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Qbtech AB
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited
Social Anxiety Disorder (SAD)
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
This study is to compare two Virtual Reality (VR)-based interventions, BVR-100 and BES-100, for the treatment of Social Anxiety Disorder (SAD).
- Trial name
- BVR-100-102 (NCT06037668)
- Testing
- BVR-100, BES-100
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sumitomo Pharma America, Inc.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Anxiety Disorders
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum.
- Trial name
- NCT00612859
- Testing
- levetiracetam
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-1 (NCT04754802)
- Testing
- PH94B Nasal Spray
- Where
- 21 sites in United States
- Volunteers
- 224 people
- Sponsor
- VistaGen Therapeutics, Inc.
Performance Anxiety
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
- Trial name
- NCT04800237
- Testing
- VQW-765
- Where
- 15 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Social Anxiety Disorder
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women.
- Trial name
- NCT02622958
- Testing
- PH94B
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Social Anxiety Disorder (Social Phobia), Social Anxiety
Efficacy and Safety of the Alena App as a Treatment for Social Anxiety Disorder
The present study is a randomised controlled trial that seeks to investigate the efficacy and safety of the Alena app as a treatment for social anxiety disorder.
- Conditions
- Social Anxiety Disorder (Social Phobia), Social Anxiety, Social Anxiety Disorder
- Trial name
- NCT05987969
- Testing
- "Alena" mobile application
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Aya Technologies Limited
Social Anxiety Disorder (SAD)
A Study of ONO-1110 in Patients With Social Anxiety Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder
- Trial name
- NCT06805565
- Testing
- ONO-1110
- Where
- 27 sites in Japan
- Volunteers
- 115 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Social Phobia
VR Mind and VR Mind+ Intervention
The aim of the study is to assess the safety and efficacy of VR Mind and VR Mind + interventions.
- Trial name
- NCT03895957
- Testing
- Virtual Reality Exposure Therapy VR Mind+, Virtual Reality Exposure Therapy VR Mind, Cognitive Behavioral Therapy
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Tomorrow Sp. z o.o.